Luis Abrishamian-Garcia, MD
Emergency Medicine · Los Angeles, CANPI 1801059266
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 98.5% of the total across 54 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 10 manufacturers reported payments, led by AbbVie at 31.0% of the total. Among emergency medicine clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 54 payments — averaging $30.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$514
- Galderma Laboratories, L.p.$295
- Medtronic$178
- Merz North America, Inc.$169
- Lumenis BE Inc$158
- Abiomed$144
- plus $198 from 4 others
Across 216 payments — averaging $5167.38 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Novartis$580K
- Pfizer$223K
- Eli Lilly$200K
- Regeneron$75K
- AstraZeneca$16K
- GSK$15K
- plus $7K from 1 others
What the payments were for
- Food & beverage$1,63198%
- Education$252%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 33 | $514 |
| Galderma Laboratories, L.p. | 10 | $295 |
| Medtronic | 1 | $178 |
| Merz North America, Inc. | 2 | $169 |
| Lumenis BE Inc | 1 | $158 |
| Abiomed | 1 | $144 |
| Intuitive Surgical | 1 | $97 |
| Boston Scientific | 2 | $47 |
| Revance Therapeutics, Inc. | 2 | $37 |
| Siemens Medical Solutions USA, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$178
- M22$158
- Impella$144
How this compares
$1,657 in reported general payments places this provider in the 95th percentile of 6,006 emergency medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cephalexin | 20 | $158 |
| Ondansetron OdtOndansetron | 15 | $152 |
Paid to pharmacies, not to this prescriber.
Other emergency medicine in Los Angeles
- Christopher PeabodyLos Angeles$163K
- Samuel BeckermanLos Angeles$81K
- Bharat KothakotaLos Angeles$51K
- Jay LeeLos Angeles$20K
- Anna Ryabets-LienhardLos Angeles$16K
- Michael BlueLone Pine$915K
- Andrew AccardiEncinitas$383K
- Fredrick Melik-AbrahamianSylmar$354K
- Graham WalkerStanford$309K
- Douglas WhiteOakland$220K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.